Cancer Biology & Medicine最新文献

筛选
英文 中文
Early-onset gastric cancer global burden profile, trends, and contributors. 早发性胃癌全球负担概况、趋势和贡献者。
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-08-20 DOI: 10.20892/j.issn.2095-3941.2025.0320
Xueyang Zhang, Boao Gao, Wei Wang
{"title":"Early-onset gastric cancer global burden profile, trends, and contributors.","authors":"Xueyang Zhang, Boao Gao, Wei Wang","doi":"10.20892/j.issn.2095-3941.2025.0320","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2025.0320","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to assess the global, regional, and national burden of early-onset gastric cancer (EOGC) and the attributable risk factors from 1990-2021 with projections extending to 2040.</p><p><strong>Methods: </strong>The EOGC burden was quantified using incidence, prevalence, mortality, and disability-adjusted life years (DALYs) with calculation of age-standardized rates. The risk factor contributions were analyzed and disparities were evaluated using the slope index of inequality. Future trends for 2021-2040 were estimated using a Bayesian age-period-cohort model.</p><p><strong>Results: </strong>There were approximately 125,000 new cases of EOGC globally in 2021 with an estimated 336,000 individuals living with EOGC and 78,000 associated deaths, contributing to 3.86 million DALYs. The highest EOGC incidence rates existed among individuals 45-49 years of age. The global age-standardized incidence, prevalence, mortality, and DALY rates demonstrated an overall decline between 1990 and 2021. Smoking and high-salt dietary intake were the leading risk factors for DALYs with regional and gender-based variations. Smoking accounted for > 10% of DALYs in Central Europe and East Asia, while high-salt dietary intake accounted for approximately 8% of DALYs. Despite the overall decline in the EOGC burden, disparities across geographic regions widened. Projections indicated a continued gradual reduction in EOGC burden through 2040.</p><p><strong>Conclusions: </strong>Although the global burden of EOGC has decreased, significant disparities persist across geographic regions, age groups, and genders. Public health interventions should combine smoking prevention strategies (e.g., youth education and tobacco taxation) with cessation programs with dietary salt reduction initiatives.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer mortality trends in China from 2013-2021 and projections to 2030. 2013-2021年中国癌症死亡率趋势及2030年预测
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-30 DOI: 10.20892/j.issn.2095-3941.2025.0158
Xin Liang, Yifei Yao, Xiang Li, Ting Gao, Xiaoqiu Dai
{"title":"Cancer mortality trends in China from 2013-2021 and projections to 2030.","authors":"Xin Liang, Yifei Yao, Xiang Li, Ting Gao, Xiaoqiu Dai","doi":"10.20892/j.issn.2095-3941.2025.0158","DOIUrl":"https://doi.org/10.20892/j.issn.2095-3941.2025.0158","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to analyze the temporal trends in cancer mortality in China from 2013-2021 and project the future trends through 2030.</p><p><strong>Methods: </strong>This study was based on the China Causes of Death Surveillance Dataset, which covers 2.37 billion person-years. Age-standardized mortality rates (ASMRs) were calculated using Segi's world standard population and the trends were evaluated <i>via</i> Joinpoint regression. Bayesian age-period-cohort models were used for mortality projections. Contributions of demographic changes (population size and age structure) and risk factors to the mortality burden were quantified using the decomposition analysis.</p><p><strong>Results: </strong>The combined ASMRs for all cancers decreased annually by 2.3%, driven by significant declines in esophageal (4.8%), stomach (4.5%), and liver cancers (2.7%). In contrast, the pancreatic and prostate cancer ASMRs increased by 2.0% and 3.4% annually, respectively. Urban areas demonstrated a more rapid decline in the combined ASMRs for all cancers [average annual percent change (AAPC) = -3.0% in urban areas <i>vs</i>. -2.0% in rural areas], highlighting persistent disparities. Population aging contributed 20%-50% to death increases between 2013 and 2021. The combined ASMRs for all cancers, like the findings of temporal trend analyses, will continue to decrease and the regional (urban and rural) difference is projected to simulate that of the temporal trend through 2030. In fact, cancer deaths are projected to reach 2.4 million by 2030.</p><p><strong>Conclusions: </strong>The cancer burden in China is facing the dual challenges of population aging and urban-rural disparities. It is necessary to prioritize rural screening, control risk factors, such as smoking and diet, and integrate more efficacious cancer prevention and control programmes into the policy to reduce mortality in the future.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Global disparities in childhood neuroblastoma: trends, burden, and inequities from 1990 to 2021. 儿童神经母细胞瘤的全球差异:1990年至2021年的趋势、负担和不平等。
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-30 DOI: 10.20892/j.issn.2095-3941.2025.0163
Rui Zhang, Yang Bi, Feifei Bao, Feixia Pan, Weize Xu, Qiang Shu, Zhigang Liu, Daqing Ma
{"title":"Global disparities in childhood neuroblastoma: trends, burden, and inequities from 1990 to 2021.","authors":"Rui Zhang, Yang Bi, Feifei Bao, Feixia Pan, Weize Xu, Qiang Shu, Zhigang Liu, Daqing Ma","doi":"10.20892/j.issn.2095-3941.2025.0163","DOIUrl":"10.20892/j.issn.2095-3941.2025.0163","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418264/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The arginine metabolism battlefield: how metabolite exchange in the tumor microenvironment shapes an immunosuppressive ecosystem. 精氨酸代谢战场:肿瘤微环境中代谢物交换如何形成免疫抑制生态系统。
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-30 DOI: 10.20892/j.issn.2095-3941.2025.0202
Yinghua Zhu, Hongde Li, Hongbo Hu, Hai Hu, Man-Li Luo
{"title":"The arginine metabolism battlefield: how metabolite exchange in the tumor microenvironment shapes an immunosuppressive ecosystem.","authors":"Yinghua Zhu, Hongde Li, Hongbo Hu, Hai Hu, Man-Li Luo","doi":"10.20892/j.issn.2095-3941.2025.0202","DOIUrl":"10.20892/j.issn.2095-3941.2025.0202","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418263/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144752514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Non-essential role of S100A9 in hematopoiesis in primary MPN and MDS mouse models. S100A9在原发性MPN和MDS小鼠模型造血中的非必要作用。
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-26 DOI: 10.20892/j.issn.2095-3941.2025.0185
Qinglin Li, Xuezhen Ma, Zhaofeng Li, Xinshu Xie, Yating Lu, Hanqi Liu, Ailing Zou, Yexin Yang, Jie Ouyang, Shuqian Xu, Yang Mei
{"title":"Non-essential role of S100A9 in hematopoiesis in primary MPN and MDS mouse models.","authors":"Qinglin Li, Xuezhen Ma, Zhaofeng Li, Xinshu Xie, Yating Lu, Hanqi Liu, Ailing Zou, Yexin Yang, Jie Ouyang, Shuqian Xu, Yang Mei","doi":"10.20892/j.issn.2095-3941.2025.0185","DOIUrl":"10.20892/j.issn.2095-3941.2025.0185","url":null,"abstract":"","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":"22 7","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728132","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Amino acids shape the metabolic and immunologic landscape in the tumor immune microenvironment: from molecular mechanisms to therapeutic strategies. 氨基酸在肿瘤免疫微环境中塑造代谢和免疫景观:从分子机制到治疗策略。
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-24 DOI: 10.20892/j.issn.2095-3941.2025.0115
Ziyou Lin, Chang Chang, Shuyu Zhao, Lan Fang, Ping Wang
{"title":"Amino acids shape the metabolic and immunologic landscape in the tumor immune microenvironment: from molecular mechanisms to therapeutic strategies.","authors":"Ziyou Lin, Chang Chang, Shuyu Zhao, Lan Fang, Ping Wang","doi":"10.20892/j.issn.2095-3941.2025.0115","DOIUrl":"10.20892/j.issn.2095-3941.2025.0115","url":null,"abstract":"<p><p>The tumor immune microenvironment (TIME) represents a complex battlefield where metabolic competition and immune evasion mechanisms converge to drive cancer progression. Amino acids, with their multifaceted biological roles, have emerged as pivotal regulators of tumor cell proliferation and immune cell functionality. The sensing mechanisms by which amino acids within the tumor microenvironment influence cellular growth, survival, and immune function are systematically explored in this review; the latest advances in understanding amino acid metabolism in tumor biology are also reviewed. In addition, the multifaceted roles of key amino acids in shaping the TIME with particular emphasis on tumor immunity and malignant growth were investigated. Finally, emerging therapeutic strategies targeting amino acid metabolism to reprogram the TIME are discussed, highlighting promising approaches, such as CAR-T cell therapy and engineered bacterial interventions. Through this comprehensive analysis, critical insights into future research directions and potential clinical translation of amino acid-targeted interventions are provided.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Organoid models in oncology: advancing precision cancer therapy and vaccine development. 肿瘤学中的类器官模型:推进精准癌症治疗和疫苗开发。
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-24 DOI: 10.20892/j.issn.2095-3941.2025.0127
Yuxuan Xiao, Yutao Li, Xilin Jing, Lin Weng, Xu Liu, Qingyun Liu, Kezhong Chen
{"title":"Organoid models in oncology: advancing precision cancer therapy and vaccine development.","authors":"Yuxuan Xiao, Yutao Li, Xilin Jing, Lin Weng, Xu Liu, Qingyun Liu, Kezhong Chen","doi":"10.20892/j.issn.2095-3941.2025.0127","DOIUrl":"10.20892/j.issn.2095-3941.2025.0127","url":null,"abstract":"<p><p>Organoids are three-dimensional stem cell-derived models that offer a more physiologically relevant representation of tumor biology compared to traditional two-dimensional cell cultures or animal models. Organoids preserve the complex tissue architecture and cellular diversity of human cancers, enabling more accurate predictions of tumor growth, metastasis, and drug responses. Integration with microfluidic platforms, such as organ-on-a-chip systems, further enhances the ability to model tumor-environment interactions in real-time. Organoids facilitate in-depth exploration of tumor heterogeneity, molecular mechanisms, and the development of personalized treatment strategies when coupled with multi-omics technologies. Organoids provide a platform for investigating tumor-immune cell interactions, which aid in the design and testing of immune-based therapies and vaccines. Taken together, these features position organoids as a transformative tool in advancing cancer research and precision medicine.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418270/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lactate and lactylation in breast cancer: current understanding and therapeutic opportunities. 乳腺癌中的乳酸和乳酸化:目前的认识和治疗机会。
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-16 DOI: 10.20892/j.issn.2095-3941.2025.0173
Lan Huang, Xuemei Chen, Meina Yan, Ze Xiang, Jian Wu
{"title":"Lactate and lactylation in breast cancer: current understanding and therapeutic opportunities.","authors":"Lan Huang, Xuemei Chen, Meina Yan, Ze Xiang, Jian Wu","doi":"10.20892/j.issn.2095-3941.2025.0173","DOIUrl":"10.20892/j.issn.2095-3941.2025.0173","url":null,"abstract":"<p><p>Breast cancer (BC) has the highest prevalence among cancers specific to women, and its incidence rates are increasing in many countries. Subtypes of BC, including HER2-positive or triple-negative BC, exhibit differing treatment responses; consequently, demand for personalized therapy is increasing, and relevant precision medicine strategies are under development. Aerobic glycolysis in cancer cells can lead to excessive lactate production, which in turn promotes lactylation and influences tumor cell behavior. Epigenetic alterations and metabolic reprogramming are prominent characteristics of tumors. Because lactate and lactylation are important in cancer, further investigation of the mechanisms underlying lactate metabolism and lactylation, and the development of therapeutic strategies targeting these processes, are topics of increasing interest. This review describes current research on lactate metabolism and lactylation in BC, thus offering new perspectives for advancing treatment and management toward more precise and personalized approaches that will ultimately increase BC survival rates and patient quality of life.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302272/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648675","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma. GPRC5A/CXCL8/ nlrp3介导的中性粒细胞胞外陷阱驱动胰腺腺癌吉西他滨-单抗紫杉醇耐药
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-15 DOI: 10.20892/j.issn.2095-3941.2025.0040
Tianyi Zhu, Qianwen Yang, Xiaozhe Qian, Xiuqi Wu, Jianchen Fang, Yuli Lin, Yukuan Feng, Jian Gao, Qing Xia
{"title":"GPRC5A/CXCL8/NLRP3-mediated neutrophil extracellular traps drive gemcitabine-nab-paclitaxel resistance in pancreatic adenocarcinoma.","authors":"Tianyi Zhu, Qianwen Yang, Xiaozhe Qian, Xiuqi Wu, Jianchen Fang, Yuli Lin, Yukuan Feng, Jian Gao, Qing Xia","doi":"10.20892/j.issn.2095-3941.2025.0040","DOIUrl":"10.20892/j.issn.2095-3941.2025.0040","url":null,"abstract":"<p><strong>Objective: </strong>Gemcitabine combined with nab-paclitaxel therapy (GnP) represents first-line chemotherapy for advanced pancreatic ductal adenocarcinoma (PDAC). However, the efficacy of GnP is diminished due to chemotherapeutic resistance induced by the tumor microenvironment (TME), the underlying mechanisms of which remain poorly understood.</p><p><strong>Methods: </strong>Clinical data from patients with PDAC who underwent GnP therapy were collected and neutrophil infiltration in tumor tissues was assessed. PDAC cell lines and a mouse model of PDAC were utilized to determine the mechanisms underlying GnP resistance and to focus on tumor-associated neutrophils and neutrophil extracellular traps (NETs).</p><p><strong>Results: </strong>GnP therapy recruited neutrophils to the TME, which resulted in the formation of NETs that contributed to therapeutic resistance in the PDAC murine model. The NET inhibitor, PAD4, enhanced the efficacy of GnP by suppressing tumor growth. Furthermore, GnP significantly upregulated CXCL8 secretion in GnP-resistant MIA PaCa-2 cells, which was mediated by increased expression of GPRC5A in PDAC cells. Screening of classic NET-derived molecules identified cell-free DNA (cfDNA) as a pleiotropic factor that promoted tumor cell proliferation and migration and thereby contributed to chemotherapeutic resistance. <i>In vivo</i> experiments revealed that the combination of GnP with siGPRC5A or DNase was more effective in reducing tumor growth and prolonging survival in PDAC-bearing mice than either treatment alone.</p><p><strong>Conclusions: </strong>The GPRC5A-CXCL8-NET-cfDNA axis has a critical role in the development of therapeutic resistance to GnP in PDAC. Targeting this axis may represent a promising strategy for overcoming GnP resistance and thereby enhancing the efficacy of chemotherapy in PDAC.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641894","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comprehensive strategies for management of postoperative hyper-progression recurrence (HPR) of hepatocellular carcinoma: a 12-year large sample multi-center study. 肝细胞癌术后超进展复发(HPR)的综合治疗策略:一项为期12年的大样本多中心研究
IF 8.4 2区 医学
Cancer Biology & Medicine Pub Date : 2025-07-11 DOI: 10.20892/j.issn.2095-3941.2024.0514
Lunan Qi, Jingxuan Xu, Yuanyuan Chen, Zhan Lu, Min Zhou, Yingwu Huang, Yongchi Ling, Hai Huang, Yuchong Peng, Tao Peng, Bangde Xiang, Liang Ma
{"title":"Comprehensive strategies for management of postoperative hyper-progression recurrence (HPR) of hepatocellular carcinoma: a 12-year large sample multi-center study.","authors":"Lunan Qi, Jingxuan Xu, Yuanyuan Chen, Zhan Lu, Min Zhou, Yingwu Huang, Yongchi Ling, Hai Huang, Yuchong Peng, Tao Peng, Bangde Xiang, Liang Ma","doi":"10.20892/j.issn.2095-3941.2024.0514","DOIUrl":"10.20892/j.issn.2095-3941.2024.0514","url":null,"abstract":"<p><strong>Objective: </strong>Hyper-progression recurrence (HPR) after hepatectomy is a specific recurrence pattern associated with extremely poor prognosis in patients with hepatocellular carcinoma (HCC). This study was aimed at investigating the probable risk factors and establishing comprehensive models for formulating clinical strategies.</p><p><strong>Methods: </strong>Overall, 16,158 patients with HCC from 8 hospitals were screened, among whom 3,125 patients who underwent R0 resection were included, and divided into development (<i>n</i> = 2,113) and validation (<i>n</i> = 1,012) cohorts. A comprehensive study of HPR predictive models and biological features was conducted.</p><p><strong>Results: </strong>Among the 3,125 enrolled patients, 506 (16.19%) developed HPR. The influence of HPR on extremely poor prognosis was reflected by recurrence features, adverse effects on systemic and liver function, and limited therapeutic options. Nine variables closely associated with HPR were identified, and incorporated into nomogram and conditional inference tree models, which successfully achieved pre- and post-operative HPR risk stratification and facilitated clinical decision-making. Multi-dimensional verification also confirmed the predictive accuracy of model combinations and their reliability in clinical applications. Furthermore, biological analyses revealed that HCCs with HPR exhibited hyperactive biological processes, inactive metabolism, and immune exhaustion features, together with high MYCN/HMGA2 co-expression, thereby enhancing understanding of the molecular events leading to HPR and providing valuable knowledge for HPR management.</p><p><strong>Conclusions: </strong>HPR after hepatectomy is associated with extremely poor prognosis and requires substantial attention. We constructed comprehensive predictive models and propose a clinical strategy for guiding HPR prevention and management.</p>","PeriodicalId":9611,"journal":{"name":"Cancer Biology & Medicine","volume":" ","pages":""},"PeriodicalIF":8.4,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12418268/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607485","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信